ADAM17 mRNA expression and pathological features of hepatocellular carcinoma
about
ADAM-12 as a diagnostic marker for the proliferation, migration and invasion in patients with small cell lung cancer.ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression.ADAM-17: the enzyme that does it all.Novel RNA oligonucleotide improves liver function and inhibits liver carcinogenesis in vivo.Systemic overexpression of TNFα-converting enzyme does not lead to enhanced shedding activity in vivoOverexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression.The cytosolic domain of protein-tyrosine kinase 7 (PTK7), generated from sequential cleavage by a disintegrin and metalloprotease 17 (ADAM17) and γ-secretase, enhances cell proliferation and migration in colon cancer cellsADAM proteases, ErbB pathways and cancer.Loss of hepatocyte ERBB3 but not EGFR impairs hepatocarcinogenesisADAMs, cell migration and cancer.Survival and apoptosis: a dysregulated balance in liver cancer.Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancerA naturally occurring HER2 carboxy-terminal fragment promotes mammary tumor growth and metastasis.Role of ADAM17 in invasion and migration of CD133-expressing liver cancer stem cells after irradiation.CX3CL1/fractalkine shedding by human hepatic stellate cells: contribution to chronic inflammation in the liverADAM17 promotes breast cancer cell malignant phenotype through EGFR-PI3K-AKT activation.The epidermal growth factor receptor: a link between inflammation and liver cancer.Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer.Hepatocyte specific TIMP3 expression prevents diet dependent fatty liver disease and hepatocellular carcinoma.MicroRNA-152 targets ADAM17 to suppress NSCLC progression.Effects of tetrandrine on glioma cell malignant phenotype via inhibition of ADAM17.ADAM17 mediates hypoxia-induced drug resistance in hepatocellular carcinoma cells through activation of EGFR/PI3K/Akt pathway.ADAM17 promotes glioma cell malignant phenotypeTumorigenicity of cortical astrocyte cell line induced by the protease ADAM17.Post-transcriptional up-regulation of ADAM17 upon epidermal growth factor receptor activation and in breast tumors.MicroRNA-145 targets the metalloprotease ADAM17 and is suppressed in renal cell carcinoma patientsExpression of tumor necrosis factor-alpha converting enzyme in liver regeneration after partial hepatectomy.Dysregulation of apoptosis in hepatocellular carcinoma cells.miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17.Overexpression of a disintegrin and metalloproteinase 21 is associated with motility, metastasis, and poor prognosis in hepatocellular carcinoma.The B7 Family Member B7-H6: a New Bane of Tumor.Global analysis of differentially expressed genes in androgen-independent prostate cancer.
P2860
Q31148772-8E524069-86D4-496D-891D-CD272AD35C04Q33346972-E9A01129-8818-494E-96DC-53343D1769C1Q33737421-9011D7E4-B196-427A-A507-9A197BA317CBQ34362849-6B65AD0F-007A-43BB-ACA6-0B8DAA0B087FQ34559443-3CBEC13D-5322-4D31-A7FD-871FF843AC0DQ34577446-DC77E19D-F96B-4731-B86E-3522AAFB7784Q36126992-3FB21FC5-3207-4033-9528-1ECCF46D092AQ36187030-D825FA65-003E-4EE7-9F2C-5F0EC5641072Q36382083-5F3128DC-9657-4B83-9544-C35A466B357AQ36471116-6944A59C-3D56-4B2B-89F6-A9F16936D526Q36740628-6100978A-D7DF-4CD9-8CF1-5A86456ABBA4Q36840255-E6EF2A6C-24DD-4703-9050-33256DA8C412Q37233360-AAFBC8BA-802F-445D-8166-473452741D45Q37269051-F90711B4-8EE1-4A94-8FA7-B3A8444E653BQ37310641-682E265D-A22E-4F8C-A8EB-125E3C934E16Q37398747-BCFA9FB2-01D2-4D9A-8AB3-D4592F8D1577Q37476452-9403A757-C433-4780-B9C9-AD56A95B755EQ38161361-7A1CE63B-90FA-4615-ABD8-8F7C374B2E99Q38656435-78FE407F-209C-455A-A80F-3907FC7C8BACQ39000373-688D8E84-086F-4D59-BEC4-646170A5FA6EQ39067520-11E060D8-B2CE-449A-A35D-E0ECFC223D55Q39159149-42B9C9C0-6F4B-4321-B58B-07CB8BF7F531Q39561009-CCF391BB-A35F-4A6E-951D-6BAEEEFB8A51Q39839864-075770C2-F7A2-4E08-90E3-2C4F5ECF47D4Q40182579-DA6A6698-5473-4953-B9DC-1A54D5CCFF51Q41412889-0F73FF4D-2808-4A0A-A603-29BA9CB7AB20Q42152278-A68AECDA-1576-4B9A-B63E-680AB72DC85CQ43166036-B8C58837-AA1A-456A-B0A5-46FD000A3309Q44055579-ECFC44DB-BAE0-4F29-A9C7-39A85FF05CF5Q47099168-26DD223C-EF69-4584-BF68-D5E358C0B361Q48098708-88033F38-8209-465C-A14E-561F80D6C62EQ51089358-F31AB5A1-9539-446F-AC88-BAD4E0B305E8
P2860
ADAM17 mRNA expression and pathological features of hepatocellular carcinoma
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
ADAM17 mRNA expression and pathological features of hepatocellular carcinoma
@ast
ADAM17 mRNA expression and pathological features of hepatocellular carcinoma
@en
type
label
ADAM17 mRNA expression and pathological features of hepatocellular carcinoma
@ast
ADAM17 mRNA expression and pathological features of hepatocellular carcinoma
@en
prefLabel
ADAM17 mRNA expression and pathological features of hepatocellular carcinoma
@ast
ADAM17 mRNA expression and pathological features of hepatocellular carcinoma
@en
P2093
P2860
P356
P1476
ADAM17 mRNA expression and pathological features of hepatocellular carcinoma
@en
P2093
Gen-Wen Huang
Lian-Yue Yang
Wei-Qun Lu
Xiang Ding
P2860
P304
P356
10.3748/WJG.V10.I18.2735
P407
P577
2004-09-01T00:00:00Z